Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : RNAi -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (455)	4/5/2006 4:11:24 PM
From: A.J. Mullen	Read Replies (2) \| Respond to of 671

"We are gratified that the US Patent Office has issued the first broad siRNA target patent to Sirna," said Bharat Chowrira, Ph.D., Vice President, Legal Affairs and Chief Patent Counsel. Both Alnylam and Sirna have claimed to have IP locks on the technology for at least two years. Now Sirna is claiming that a patent just awarded is the first one. I also heard that the fundamental IP was held by a university (Wisconsin?) and that they were licensing it on a non-exclusive basis to all-comers. I wish I knew the truth. Ashley